Traws Pharma secures $10 million PIPE with $50 million warrant upside for flu trial

Traws Pharma has entered into a securities purchase agreement for a PIPE financing expected to provide $10 million in gross proceeds, with up to $50 million additional from milestone-based warrants. The funding will support the company's influenza programme through a human challenge trial in the UK following MHRA approval.

Traws Pharma has entered into a securities purchase agreement with new and existing institutional and accredited investors for a private investment in public equity financing expected to provide approximately $10.0 million in gross proceeds at closing, according to an official announcement. The financing includes up to $50 million of additional gross proceeds from milestone-based and three-year warrants, positioning the company to complete its influenza human challenge trial in the United Kingdom.

Traws Pharma is a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases. The April 2026 financing consists of $10.0 million of upfront gross proceeds from the sale of common stock at $1.6730 per share, a Series A warrant for up to $10.0 million upon MHRA approval to conduct a human challenge trial, a Series B warrant for up to $10.0 million following shareholder approval and trial data announcement, and a Series C warrant for up to $30.0 million with a three-year term. The PIPE was priced at-the-market under Nasdaq rules, with warrants having exercise prices equal to the deal price.

This development matters for the biopharmaceutical industry, where milestone-based financing structures align investor returns with clinical progress. The human challenge trial model for influenza enables controlled efficacy assessment but requires regulatory approval from the MHRA.

For the infectious disease therapeutics sector, the funding advances an influenza programme at a time when pandemic preparedness remains a priority. Cantor Fitzgerald acted as lead placement agent, with Citizens JMP Securities and Tungsten Advisors as co-placement agents. The securities were sold in a private transaction exempt from registration under the Securities Act, with resale registration rights granted to investors.